Everolimus plus exemestane as first-line therapy in HR( ), HER2 (-) advanced breast cancer in BOLERO-2.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33147255" target="_blank" >RIV/61989592:15110/14:33147255 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1007/s10549-013-2814-5" target="_blank" >http://dx.doi.org/10.1007/s10549-013-2814-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s10549-013-2814-5" target="_blank" >10.1007/s10549-013-2814-5</a>

Result language
angličtina
Original language name
Everolimus plus exemestane as first-line therapy in HR( ), HER2 (-) advanced breast cancer in BOLERO-2.
Original language description
The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (HR(+)), human epidermal growth factor receptor-2-negative (HER2(-)) advanced breast cancer recurring/progressing after a nonsteroidal aromatase inhibitor (NSAI) were randomly assigned (2:1) to receive EVE (10mg/day) + EXE (25 mg/day) or placebo (PBO) + EXE. The primary endpoint was progression-free survival (PFS) by local assessment.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)